Skip to content
Screener

CG Oncology CGON Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
11.1%+0.1pp
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$15.42M-9.3%
UroGen Pharma logo
UroGen PharmaURGN
$2.81M
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$1.57M+235%
Immunome logo
ImmunomeIMNM
$2.83M-32.1%
Replimune Group logo
Replimune GroupREPL
10.4%+0.1pp

Other financials

Income statement

See full
Revenue$1.2M
Operating income-$86.4M-77.3%
Net income-$79.1M-90.8%
EPS (diluted)-$0.90-66.7%

Balance sheet

See full
Cash & equivalents$19.6M+34.3%
Total debt$8.8M+787%
Total equity$1.0B+53.5%
Total assets$1.1B+54.8%

Cash flow

See full
Operating cash flow-$46.4M-66.0%
CapEx$468.0K+3,243%
Free cash flow-$46.9M-67.6%

Valuation

See full
Market cap$6.6B+242%
Enterprise value$6.59B+244%
P/S1,060×-2,439×

Profitability

See full
Operating margin-4,056.2%-1,873pp
Net margin-3,602.7%-1,650pp
FCF margin-2,879.6%-1,307pp

Returns & leverage

See full
Return on equity-26.4%+9.3pp
Debt / equity0.0×
Current ratio22.2×+0.1×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: CG Oncology’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336918
AssetsJune 30, 2026 / (unaudited)December 31, 2025
Prepaid expenses and other current assets19,94915,067
Total current assets1,049,647759,475
Property and equipment, net14,70715,596
Operating lease right-of-use assets5,7303,971
Intangible assets, net545575
Goodwill10,29710,297
Other assets4,7291,678
Total assets$1,085,655$791,592

Item 1. Financial Statements.

FAQ

What is CG Oncology's operating lease ROU assets?
CG Oncology (CGON) reported operating lease ROU assets of $5.73M in Q2 2026.
How has CG Oncology's operating lease ROU assets changed year-over-year?
CG Oncology's operating lease ROU assets increased by 493.8% year-over-year, from $965K to $5.73M.
What is the long-term trend for CG Oncology's operating lease ROU assets?
Over 2 years (2023 to 2025), CG Oncology's operating lease ROU assets has grown at a 206.8% compound annual growth rate (CAGR), from $422K to $3.97M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about CG Oncology's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude